Abstract
Erectile dysfunction (ED) is frequently associated with injury to the cavernous nerve sustained during pelvic surgery. Functional recovery from cavernous nerve injury is generally incomplete and occurs over an extended time frame. We employed a therapeutic gene transfer approach with herpes simplex virus (HSV) vector expressing glial cell line-derived neurotrophic factor (GDNF). Rat cavernous nerve was injured bilaterally using a clamp and dry ice. For HSV-treated groups, 20 μl of purified vector stock was administered directly to and around the damaged nerve. Delivery of an HSV vector expressing both green fluorescent protein (GFP) and lacZ (HSV-LacZ) was used as a control. Intracavernous pressure along with systemic arterial pressure (ICP/AP) was measured 2 and 4 weeks after the nerve injury. Fluorogold (FG) was injected into the penile crus 7 days before killing to assess nerve survival. Approximately 60% of major pelvic ganglion (MPG) cells were GFP positive after viral administration. At 4 weeks after nerve injury, rats treated with HSV-GDNF exhibited significant recovery of ICP/AP compared with control vector or untreated groups. The HSV-GDNF group also yielded more FG-positive MPG cells than the control vector group. HSV vector-mediated delivery of GDNF presents a viable approach for the treatment of ED following cavernous nerve injury.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR et al. Patient reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997; 89: 1117–1123.
Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT . Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164: 1929–1934.
Shimizu T, Hisasue S, Sato Y, Kato R, Kobayashi K, Tsukamoto T . Erectile dysfunction following nerve-sparing radical retropubic prostatectomy and its treatment with sildenafil. Int J Urol 2005; 12: 552–557.
Quinlan DM, Nelson RJ, Walsh PC . Cavernous nerve grafts restore erectile function in denervated rats. J Urol 1991; 145: 380–383.
Hisasue S, Kato R, Sato Y, Suetomi T, Tabata Y, Tsukamoto T . Cavernous nerve reconstruction with a biodegradable conduit graft and collagen sponge in the rat. J Urol 2005; 173: 286–291.
Sezen SF, Hoke A, Burnett AL, Snyder SH . Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7: 1073–1074.
Hayashi N, Minor TX, Carrion R, Price R, Nunes L, Lue TF . The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model. J Urol 2006; 176: 824–829.
Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int 2004; 94: 904–909.
Kendirci M, Zsengeller Z, Bivalacqua TJ, Gur S, Usta MF, Chen M et al. Poly (adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J Urol 2005; 174: 2054–2059.
Chen KC, Minor TX, Rahman NU, Ho HC, Nunes L, Lue TF . The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence. BJU Int 2005; 95: 1077–1080.
Bochinski D, Hsieh PS, Nunes L, Lin GT, Lin CS, Spencer EM et al. Effect of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 complex in cavernous nerve cryoablation. Int J Impot Res 2004; 16: 418–423.
Bivalacqua TJ, Deng W, Champion HC, Hellstrom WJ, Kadowitz PJ . Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpora cavernosa for erectile dysfunction. Methods Mol Biol 2004; 279: 173–185.
Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002; 67: 1033–1041.
Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004; 287: H1544–H1553.
Melman A, Bar-Chama N, McCullough A, Davies K, Christ G . The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2005; 48: 314–318.
Markus A, Patel TD, Snider WD . Neurotrophic factors and axonal growth. Curr Opin Neurobiol 2003; 12: 523–531.
Laurikainen A, Hiltunen JO, Vanhatalo S, Klinge E, Saarma M . Glial cell line-derived neurotrophic factor is expressed in penis of adult rat and retrogradely transported in penile parasympathetic and sensory nerves. Cell Tissue Res 2000; 302: 321–329.
Wanigasekara Y, Keast JR . Neurturin has multiple neurotrophic effects on adult rat sacral parasympathetic ganglion neurons. Eur J Neurosci 2005; 22: 595–604.
Palma CA, Keast JR . Structural effects and potential changes in growth factor signalling in penis-projecting autonomic neurons after axotomy. BMC Neurosci 2006; 7: 41.
Pradier P, Jalenques I, Dalle M, Reuling R, Despres G, Romand R . Distribution and metabolism patterns of plasma 7S- and beta-NGF in the adult male rat. J Physiol Paris 1994; 88: 273–277.
Tria MA, Fusco M, Vantini G, Mariot R . Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 1994; 127: 178–183.
Lindsay RM . Therapeutic potential of the neurotrophins and neurotrophin–CNTF combinations in peripheral neuropathies and motor neuron diseases. Ciba Found Symp 1996; 196: 39–48.
Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA . Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695–702.
Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284: 2215–2221.
Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994; 36: 244–246.
Thoenen H, Sendtner M . Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002; 5: 1046–1050.
Mata M, Glorioso JC, Fink DJ . Gene transfer to the nervous system: prospects for novel treatments directed at diseases of the aging nervous system. J Gerontol A Biol Sci Med Sci 2003; 58: M1111–M1118.
Fink DJ, Glorioso J, Mata M . Therapeutic gene transfer with herpes-based vectors: studies in Parkinson's disease and motor nerve regeneration. Exp Neurol 2003; 184: S19–S24.
Kay MA, Glorioso JC, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 200; 7: 33–40.
Samaniego L, Webb A, DeLuca N . Functional interaction between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995; 69: 5705–5715.
Samaniego L, Naxin W, DeLuca N . The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71: 4614–4625.
Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF et al. Replication-defective HSV vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319–11320.
Krisky D, Marconi P, Oligino T, Rouse R, Fink D, Glorioso J . Rapid method for construction of recombinant HSV gene transfer vectors. Gene Therapy 1997; 4: 1120–1125.
Jiang C, Wechuck JB, Goins WF, Krisky DM, Wolfe D, Ataai MM et al. Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol 2004; 78: 8994–9006.
Ozuer A, Wechuck JB, Russell B, Wolfe D, Goins WF, Glorioso JC et al. Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors. Biotechnol Prog 2002; 18: 476–482.
Ozuer A, Wechuck JB, Goins WF, Wolfe D, Glorioso JC, Ataai MM . Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng 2002; 77: 685–692.
Goins WF, Yoshimura N, Phelan MW, Yokoyama T, Fraser MO, Ozawa H et al. Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol 2001; 165: 1748–1754.
Sasaki K, Chancellor MB, Goins WF, Phelan MW, Glorioso JC, de Groat WC et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 2004; 53: 2723–2730.
Bennett NE, Kim JH, Wolfe DP, Sasaki K, Yoshimura N, Goins WF et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005; 173: 1820–1824.
Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ . Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 2005; 57: 914–918.
Chattopadhyay M, Goss J, Wolfe D, Goins WC, Huang S, Glorioso JC et al. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004; 127: 929–939.
Chattopadhyay M, Wolfe D, Huang S, Goss J, Glorioso JC, Mata M et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002; 51: 19–27.
Chattopadhyay M, Goss J, Lacomis D, Goins WC, Glorioso JC, Mata M et al. Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci 2003; 17: 732–740.
Natsume A, Mata M, Wolfe D, Oligino T, Goss J, Huang S et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect. J Neurotrauma 2002; 19: 61–68.
Natsume A, Wolfe D, Hu J, Huang S, Puskovic V, Glorioso JC et al. Enhanced functional recovery after proximal nerve root injury by vector-mediated gene transfer. Exp Neurol 2003; 184: 878–886.
Jung GW, Spencer EM, Lue TF . Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats. J Urol 1998; 160: 1899–1904.
Tamura M, Kagawa S, Tsuruo Y, Ishimura K, Kimura K, Kawanishi Y . Localization of NADPH diaphorase and vasoactive intestinal polypeptide-containing neurons in the efferent pathway to the rat corpus cavernosum. Eur Urol 1997; 32: 100–104.
Kato R, Kiryu-Seo S, Sato Y, Hisasue S, Tsukamoto T, Kiyama H . Cavernous nerve injury elicits GAP-43 mRNA expression but not regeneration of injured pelvic ganglion neurons. Brain Res 2003; 986: 166–173.
Matsuura S, Obara T, Tsuchiya N, Suzuki Y, Habuchi T . Cavernous nerve regeneration by biodegradable alginate gel sponge sheet placement without sutures. Urology 2006; 68: 1366–1371.
Goins WF, Sternberg LR, Croen KD, Krause PR, Hendricks RL, Fink DJ et al. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol 1994; 68: 2239–2252.
Goins WF, Lee KA, Cavalcoli J, O'Malley M, Fink DJ, DeKosky ST et al. Herpes simplex virus vector mediated expression of biologically active nerve growth factor. J Virol 1999; 73: 519–532.
Rock DL, Fraser NW . Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region. J Virol 1985; 55: 849–852.
Wang CY, Yang F, He XP, Je HS, Zhou JZ, Eckermann K et al. Regulation of neuromuscular synapse development by glial cell line-derived neurotrophic factor and neurturin. J Biol Chem 2002; 277: 10614–10625.
Hammarberg H, Piehl F, Cullheim S, Fjell J, Hokfelt T, Fried K . GDNF mRNA in Schwann cells and DRG satellite cells after chronic sciatic nerve injury. NeuroReport 1996; 7: 857–860.
Keast JR . Unusual autonomic ganglia: connections, chemistry, and plasticity of pelvic ganglia. Int Rev Cytol 1999; 193: 1–69.
Carrier S, Zvara P, Nunes L, Kour NW, Rehman J, Lue TF . Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol 1995; 153: 1722–1727.
El-Sakka AI, Hassan MU, Selph C, Perinchery G, Dahiya R, Lue TF . Effect of cavernous nerve freezing on protein and gene expression of nitric oxide synthase in the rat penis and pelvic ganglia. J Urol 1998; 160: 2245–2252.
Dail WG, Harji F, Gonzales J, Galindo R . Multiple vasodilator pathways from the pelvic plexus to the penis of the rat. Int J Impot Res 1999; 11: 277–285.
Kepper ME, Keast JR . Specific targeting of ganglion cell sprouts provides an additional mechanism for restoring peripheral motor circuits in pelvic ganglia after spinal nerve damage. J Neurosci 1998; 18: 7987–7995.
Jung GW, Kwak JY, Yoon S, Yoon JH, Lue TF . IGF-I and TGF-beta2 have a key role on regeneration of nitric oxide synthase (NOS)-containing nerves after cavernous neurotomy in rats. Int J Impot Res 1999; 11: 247–259.
Natsume A, Mata M, Goss J, Huang S, Wolfe D, Oligino T et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp Neurol 2001; 169: 231–238.
Chuang YC, Fraser MO, Yu Y, Beckel JM, Seki S, Nakanishi Y et al. Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1302–R1310.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kato, R., Wolfe, D., Coyle, C. et al. Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther 14, 1344–1352 (2007). https://doi.org/10.1038/sj.gt.3302990
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302990
Keywords
This article is cited by
-
Towards clinical application of tissue engineering for erectile penile regeneration
Nature Reviews Urology (2019)
-
Landmarks in erectile function recovery after radical prostatectomy
Nature Reviews Urology (2015)
-
Emerging tools for erectile dysfunction: a role for regenerative medicine
Nature Reviews Urology (2012)
-
Hepatocyte growth factor incorporated into herpes simplex virus vector accelerates facial nerve regeneration after crush injury
Gene Therapy (2011)
-
Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction
Current Urology Reports (2011)